Neoadjuvant Therapy for HER2+ Early Breast Cancer

Video

Neoadjuvant Therapy for HER2+ Early Breast Cancer

  • A 53-year-old woman was referred to a breast surgeon after finding a mass in her left breast
    • PMH: unremarkable
    • FH: no history of cancer in first-degree relatives
    • PE: revealed a 6 X 5-cm, non-fixed mass in the left inferior breast without skin changes or nipple discharge, and palpable lymphadenopathy in the left axilla
    • ROS: clear
  • Mammogram confirmed a left-sided, poorly defined spiculated mass. Ultrasound shows a 5.3-cm solid mass and enlargement of 2 left axillary nodes with thickened cortex
  • Pathology results:
    • Core needle biopsy from the breast mass confirmed grade 3 invasive ductal carcinoma
      • ER—,PR—,HER2IHC 3+
      • FISH,HER2copy number, 15;HER2:CEP17 ratio, 7
    • Fine-needle aspiration of one left axillary lymph nodes was positive for carcinoma
  • Staging: T2bN1M0
Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC

Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC

April 22nd 2024
Article

During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.

Read More

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022
Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen

Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

April 18th 2024
Article

The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.

Read More

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25th 2020
Podcast

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Listen

FDA Accepts BLA for Dato-DXd in HR+/HER2– Breast Cancer

FDA Accepts BLA for Dato-DXd in HR+/HER2– Breast Cancer

April 2nd 2024
Article

The biologics license application from the FDA is supported by data from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in HR-positive, HER2-negative breast cancer.

Read More

Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer

Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer

March 29th 2024
Article

During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.

Read More